| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000247 | BKPyv | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS46000268 | BKPyv | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30003768 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30013351 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30008906 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30003769 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30016333 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30016334 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30008907 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30000694 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C1 |
|---|---|
| DrugBank ID | DB00396 |
| Drug Name | Progesterone |
| Target ID | BE0000794 |
| UniProt ID | P04150 |
| Regulation Type | partial agonist |
| PubMed IDs | 18060946; 2214763; 14617569 |
| Citations | Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN: Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol. 2007 Dec;197(6):599.e1-7.@@Xu XF, Hoebeke J, Bjorntorp P: Progestin binds to the glucocorticoid receptor and mediates antiglucocorticoid effect in rat adipose precursor cells. J Steroid Biochem. 1990 Aug 14;36(5):465-71.@@Leo JC, Guo C, Woon CT, Aw SE, Lin VC: Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology. 2004 Mar;145(3):1314-21. doi: 10.1210/en.2003-0732. Epub 2003 Nov 14. |
| Groups | Approved; Vet_approved |
| Direct Classification | Gluco/mineralocorticoids, progestogins and derivatives |
| SMILES | [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | PA451123 |
| ChEMBL | CHEMBL103 |
